New DNA vaccine aims to keep liver cancer at bay after surgery

NCT ID NCT07324304

Recruiting now Disease control Sponsor: Newish Technology (Beijing) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a DNA vaccine called NWRD06 in 30 people with a specific type of liver cancer (GPC3-positive) who have had surgery to remove their tumors. The vaccine is given as a shot followed by a mild electric pulse to help it enter cells. The goal is to see if it can keep the cancer from coming back for at least 72 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NWRD06 DNA plasmid vaccine
What this could lead to: If successful, this could help prevent liver cancer from coming back after surgery, offering a new way to control the disease.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply widely. The vaccine may not prevent recurrence and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Beijing You'an Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100000, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Peking Union Medical College Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100730, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310016, China
The Fifth Medical Center of Chinese PLA General Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.